New therapeutic targets in the management of urothelial carcinoma of the bladder

Open Access Journal of Urology

Volumn 5, Issue 1, 2013, Pages 53-65

  Sverrisson, Einar F ^a   Espiritu, Patrick N ^a   Spiess, Philippe E ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Intravesical agents; Systemic therapies; Targeted therapy

Indexed keywords

AFLIBERCEPT; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; BCG VACCINE; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOVITINIB; DOXORUBICIN; EPIRUBICIN; GEFITINIB; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; MITOMYCIN; PACLITAXEL; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; THIOTEPA; TRASTUZUMAB; UNINDEXED DRUG; VALRUBICIN; VASCULOTROPIN INHIBITOR; VINBLASTINE;

ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; BLADDER CARCINOMA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CARCINOMA IN SITU; CLINICAL EFFECTIVENESS; CYSTECTOMY; CYSTITIS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HEAD AND NECK TUMOR; HUMAN; KIDNEY CARCINOMA; LOADING DRUG DOSE; LOW DRUG DOSE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NON MUSCLE INVASIVE BLADDER CANCER; NONHUMAN; RECURRENT CANCER; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT DURATION; TREATMENT PLANNING;

EID: 84874676663     PISSN: None     EISSN: 11791551     Source Type: Journal    
DOI: 10.2147/RRU.S29131     Document Type: Article

References (85)

1. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009;27(3): 289-293.
2. Herr HW. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol. 2000;163(1):60-61; discussion 61-62.
3. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol. 2000;164(3 Pt 1):680-684.
4. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466-475; discussion 475-477.
5. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859-866.
6. Stein JP, Skinner DG. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol. 2006; 24(3):296-304.
7. Efstathiou JA, Spiegel DY, Shipley WU, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol. 2012;61(4):705-711.
8. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220-241.
9. Fedeli U, Fedewa SA, Ward EM. Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. J Urol. 2011;185(1):72-78.
10. Dash A, Galsky MD, Vickers AJ, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer. 2006;107(3): 506-513.
11. Schrag D, Mitra N, Xu F, et al. Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. Urology. 2005;65(6):1118-1125.
12. Grimm MO, Steinhoff C, Simon X, Spiegelhalder P, Ackermann R, Vogeli TA. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol. 2003;170(2 Pt 1): 433-437.
13. Dutta SC, Smith JA Jr, Shappell SB, Coffey CS, Chang SS, Cookson MS. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol. 2001;166(2):490-493.
14. Bladder Cancer Version 2. Jenkintown (PA): National Comprehensive Cancer Network (NCCN); 2011. Clinical Practice Guidelines in Oncology, Version 2. 2012. Available from: http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf. Accessed July 18, 2012.
15. Babjuk M, Oosterlinck W, Sylvester R, et al; European Association of Urology (EAU). EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011;59(6):997-1008.
16. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol. 2007;178(6):2314-2330.
17. O'Donnell MA. Advances in the management of superficial bladder cancer. Semin Oncol. 2007;34(2):85-97.
18. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124-1129.
19. Sylvester RJ, van der MA, Lamm DL. Intravesical bacillus CalmetteGuerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5):1964-1970.
20. van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV. Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol. 2003;44(4):429-434.
21. Rawls WH, Lamm DL, Lowe BA, et al. Fatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancer. J Urol. 1990;144(6):1328-1330.
22. Lamm DL, Blumenstein BA, Crawford ED, et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette Guerin for transitional-cell carcinoma of the bladder. N Engl J Med. 1991;325(17):1205-1209.
23. Witjes JA, Hendricksen K. Intravesical pharmacotherapy for nonmuscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results. Eur Urol. 2008;53(1):45-52.
24. Nadler RB, Catalona WJ, Hudson MA, Ratliff TL. Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. J Urol. 1994;152(2 Pt 1):367-373.
25. O'Donnell MA, Krohn J, DeWolf WC. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus CalmetteGuerin alone previously failed. J Urol. 2001;166(4):1300-1304, discussion 1304-1305.
26. Joudi FN, Smith BJ, O'Donnell MA. Final results from a national multicenter Phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol. 2006;24(4):344-348.
27. Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus calmetteguerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol. 2005;174(1):86-91; discussion 91-92.
28. Shelley MD, Court JB, Kynaston H, Wilt TJ, Coles B, Mason M. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev. 2003;3: CD003231.
29. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004;171(6 Pt 1): 2186-2190, quiz 2435.
30. Steinberg G, Bahnson R, Brosman S, Middleton R, Wajsman Z, Wehle M. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol. 2000;163(3):761-767.
31. Association of Urogenital Oncology (AUO). Limited vs Extended Lymphadenectomy LEA. In: ClinicalTrials.gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2010 [updated September 7, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT01215071. NLM identifier: NCT01215071. Accessed November 19, 2012.
32. S1011: Radical cystectomy for bladder cancer: how many lymph nodes to take? [webpage on the Internet] SWOG (formerly Southwestern Oncology Group), 2011. Available from: http://www.swog.org/Visitors/newsletters/2011/08/index.asp?a=s1011. Accessed November 19, 2012.
33. Spiess PE, Kassouf W, Brown G, et al. Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach? Urology. 2006;67(3):466-471.
34. Rodel C, Grabenbauer GG, Kuhn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002;20(14):3061-3071.
35. Shipley WU, Winter KA, Kaufman DS, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol. 1998;16(11):3576-3583.
36. James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366(16):1477-1488.
37. Stenzl A, Cowan NC, De Santis M, et al. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol. 2011;59(6):1009-1018.
38. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48(2):202-205; discussion 205-206.
39. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602-4608.
40. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18(17):3068-3077.
41. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol. 2005;48(2):189-199; discussion 199-201.
42. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22): 3584-3590.
43. Bellmunt J, Gonzalez-Larriba JL, Prior C, et al. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol. 2011;22(12):2646-2653.
44. Gallagher DJ, Milowsky MI, Gerst SR, et al. Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol. 2010;28(8): 1373-1379.
45. Sridhar SS, Winquist E, Eisen A, et al. A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Invest New Drugs. 2011;29(5):1045-1049.
46. Dreicer R, Li H, Stein M, et al. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer. 2009;115(18):4090-4095.
47. Li Y, Yang X, Su LJ, Flaig TW. Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells. Urology. 2011;78(1):233. e7-e13.
48. Necchi A, Mariani L, Zaffaroni N, et al. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol. 2012;13(8):810-816.
49. Lamont FR, Tomlinson DC, Cooper PA, Shnyder SD, Chester JD, Knowles MA. Small molecule FGF receptor inhibitors block FGFRdependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer. 2011;104(1):75-82.
50. Hahn NM, Stadler WM, Zon RT, et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol. 2011;29(12):1525-1530.
51. Twardowski P, Stadler WM, Frankel P, et al. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology. 2010;76(4):923-926.
52. Lonn U, Lonn S, Friberg S, Nilsson B, Silfversward C, Stenkvist B. Prognostic value of amplification of c-erb-B2 in bladder carcinoma. Clin Cancer Res. 1995;1(10):1189-1194.
53. Jimenez RE, Hussain M, Bianco FJ Jr, et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res. 2001;7(8):2440-2447.
54. Wulfing C, Machiels JP, Richel DJ, et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer. 2009;115(13):2881-2890.
55. Salzberg M, Borner M, Bauer JA, Morant R, Rauch D, Rochlitz C. Trastuzumab (Herceptin) in patients with HER-2-overexpressing meta-static or locally advanced transitional cell carcinoma of the bladder: report on 7 patients. Eur J Cancer. 2006;42(15):2660-2661.
56. Peyromaure M, Scotte F, Amsellem-Ouazana D, Vieillefond A, Oudard S, Beuzeboc P. Trastuzumab (Herceptin) in metastatic transitional cell carcinoma of the urinary tract: report on six patients. Eur Urol. 2005;48(5):771-775; discussion 775-778.
57. Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol. 2007;25(16):2218-2224.
58. Cheng J, Huang H, Zhang ZT, et al. Overexpression of epidermal growth factor receptor in urothelium elicits urothelial hyperplasia and promotes bladder tumor growth. Cancer Res. 2002;62(14):4157-4163.
59. Neal DE, Marsh C, Bennett MK, et al. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet. 1985;1(8425):366-368.
60. Wong YN, Litwin S, Vaughn D, et al. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J Clin Oncol. 2012;30(28):3545-3551.
61. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebocontrolled phase III trial. Lancet. 2008;372(9637):449-456.
62. Tickoo SK, Milowsky MI, Dhar N, et al. Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications. BJU Int. 2011; 107(5):844-849.
63. Mansure JJ, Nassim R, Chevalier S, Rocha J, Scarlata E, Kassouf W. Inhibition of mammalian target of rapamycin as a therapeutic strat-egy in the management of bladder cancer. Cancer Biol Ther. 2009; 8(24):2339-2347.
64. Seront E, Rottey S, Sautois B, et al. Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Ann Oncol. 2012;23(10):2663-2670.
65. Milowsky MI, Regazzi AM, Garcia-Grossman IR, et al. Final results of a phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium. J Clin Oncol. 2011;29(Suppl): Abstr 4606.
66. Gerullis H, Eimer C, Ecke TH, et al. A phase II trial of temsirolimus in second-line metastatic urothelial cancer. Med Oncol. 2012;29(4):2870-2876.
67. Juanpere N, Agell L, Lorenzo M, et al. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associatedwith AKT but not with MAPK pathway activation in urothelial bladder cancer. Hum Pathol. 2012;43(10):1573-1582.
68. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010;28(6):1075-1083.
69. Molins JB, Werner L, Guix M, et al. PI3KCA mutations in advanced urothelial carcinoma: a potential therapeutic target? 2012;30(Suppl 15): Abstr 4582.
70. Sharma P, Gnjatic S, Jungbluth AA, et al. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NYESO-1 T-cell epitope in a patient with bladder cancer. Cancer Immun. 2003;3:19.
71. Sharma P, Bajorin DF, Jungbluth AA, Herr H, Old LJ, Gnjatic S. Immune responses detected in urothelial carcinoma patients after vacci-nation with NY-ESO-1 protein plus BCG and GM-CSF. J Immunother. 2008;31(9):849-857.
72. Zhang P, Wang J, Wang D, et al. Dendritic cell vaccine modified by Ag85A gene enhances anti-tumor immunity against bladder cancer. Int Immunopharmacol. 2012;14(3):252-260.
73. Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC. Tumor content of the antiapoptosis molecule survivin and recurrence of bladdercancer. N Engl J Med. 1999;341(6):452-453.
74. Kitamura H, Torigoe T, Honma I, et al. Expression and antigenicity of survivin, an inhibitor of apoptosis family member, in bladder cancer:implications for specific immunotherapy. Urology. 2006;67(5): 955-959.
75. Hirohashi Y, Torigoe T, Maeda A, et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res. 2002;8(6):1731-1739.
76. Honma I, Kitamura H, Torigoe T, et al. Phase I clinical study of antiapoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer. Cancer Immunol Immunother. 2009;58(11):1801-1807.
77. Carthon BC, Wolchok JD, Yuan J, et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res. 2010;16(10):2861-2871.
78. Liakou CI, Kamat A, Tang DN, et al. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A. 2008;105(39):14987-14992.
79. Hendricksen K, Gleason D,Young JM, et al. Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer. J Urol. 2008;180(1):116-120.
80. Hendricksen K, Cornel EB, de Reijke TM, Arentsen HC, Chawla S, Witjes JA. Phase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer. J Urol. 2012;187(4):1195-1199.
81. Kowalski M, Entwistle J, Cizeau J, et al. A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCGintolerant patients. Drug Des Devel Ther. 2010;4:313-320.
82. Brunner A, Prelog M, Verdorfer I, Tzankov A, Mikuz G, Ensinger C.EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder. J Clin Pathol. 2008;61(3):307-310.
83. Kowalski M, Guindon J, Brazas L, et al. A Phase II study of oportuzumabmonatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guerin. J Urol. 2012;188(5):1712-1718.
84. Ristimaki A, Nieminen O, Saukkonen K, Hotakainen K, Nordling S, Haglund C. Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol. 2001;158(3): 849-853.
85. Gulec M, Akin H, Yuce HH, et al. Adenosine deaminase and xanthine oxidase activities in bladder washing fluid from patients with bladder cancer: a preliminary study. Clin Biochem. 2003;36(3):193-196.